![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TRMT2B |
Gene summary for TRMT2B |
![]() |
Gene information | Species | Human | Gene symbol | TRMT2B | Gene ID | 79979 |
Gene name | tRNA methyltransferase 2 homolog B | |
Gene Alias | CXorf34 | |
Cytomap | Xq22.1 | |
Gene Type | protein-coding | GO ID | GO:0001510 | UniProtAcc | A0A024RCF5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79979 | TRMT2B | HCC2_Meng | Human | Liver | HCC | 1.49e-07 | 5.52e-02 | 0.0107 |
79979 | TRMT2B | HCC1 | Human | Liver | HCC | 5.61e-06 | 9.09e-01 | 0.5336 |
79979 | TRMT2B | HCC2 | Human | Liver | HCC | 6.22e-15 | 1.65e+00 | 0.5341 |
79979 | TRMT2B | HCC5 | Human | Liver | HCC | 1.31e-13 | 1.47e+00 | 0.4932 |
79979 | TRMT2B | S028 | Human | Liver | HCC | 1.10e-06 | 2.97e-01 | 0.2503 |
79979 | TRMT2B | S029 | Human | Liver | HCC | 3.47e-03 | 2.12e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
GO:0008033 | Liver | HCC | tRNA processing | 87/7958 | 127/18723 | 2.66e-09 | 7.23e-08 | 87 |
GO:00434141 | Liver | HCC | macromolecule methylation | 183/7958 | 316/18723 | 2.00e-08 | 4.72e-07 | 183 |
GO:0032259 | Liver | HCC | methylation | 206/7958 | 364/18723 | 3.35e-08 | 7.53e-07 | 206 |
GO:0006399 | Liver | HCC | tRNA metabolic process | 108/7958 | 179/18723 | 1.07e-06 | 1.59e-05 | 108 |
GO:0009451 | Liver | HCC | RNA modification | 101/7958 | 167/18723 | 2.02e-06 | 2.78e-05 | 101 |
GO:0006400 | Liver | HCC | tRNA modification | 60/7958 | 90/18723 | 3.09e-06 | 4.09e-05 | 60 |
GO:0001510 | Liver | HCC | RNA methylation | 53/7958 | 83/18723 | 6.96e-05 | 6.29e-04 | 53 |
GO:0030488 | Liver | HCC | tRNA methylation | 29/7958 | 41/18723 | 2.38e-04 | 1.79e-03 | 29 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TRMT2B | SNV | Missense_Mutation | c.1148N>A | p.Arg383Lys | p.R383K | Q96GJ1 | protein_coding | tolerated(0.56) | benign(0.04) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
TRMT2B | SNV | Missense_Mutation | novel | c.833C>T | p.Ser278Leu | p.S278L | Q96GJ1 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-AC-A6IX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TRMT2B | SNV | Missense_Mutation | c.1240N>T | p.Asp414Tyr | p.D414Y | Q96GJ1 | protein_coding | deleterious(0.04) | benign(0.396) | TCGA-BH-A1EV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
TRMT2B | insertion | Nonsense_Mutation | novel | c.741_742insAGAATGTAGATGTGAGAGTGTCCACATGG | p.Gln248ArgfsTer3 | p.Q248Rfs*3 | Q96GJ1 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
TRMT2B | insertion | In_Frame_Ins | novel | c.451_452insCCACTAACT | p.Gly151delinsAlaThrAsnCys | p.G151delinsATNC | Q96GJ1 | protein_coding | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | ||
TRMT2B | insertion | Nonsense_Mutation | novel | c.450_451insTCCACTCTGTAGTTAA | p.Gly151SerfsTer4 | p.G151Sfs*4 | Q96GJ1 | protein_coding | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | ||
TRMT2B | SNV | Missense_Mutation | c.955G>T | p.Asp319Tyr | p.D319Y | Q96GJ1 | protein_coding | deleterious(0.01) | benign(0.07) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TRMT2B | SNV | Missense_Mutation | c.153T>G | p.Asp51Glu | p.D51E | Q96GJ1 | protein_coding | tolerated(0.13) | benign(0.005) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TRMT2B | SNV | Missense_Mutation | novel | c.170N>A | p.Ala57Asp | p.A57D | Q96GJ1 | protein_coding | tolerated(0.1) | benign(0.014) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
TRMT2B | SNV | Missense_Mutation | novel | c.635N>T | p.Ser212Phe | p.S212F | Q96GJ1 | protein_coding | deleterious(0) | possibly_damaging(0.644) | TCGA-MA-AA3Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |